Determination of Heavy Metal Ions in Tobacco and Tobacco Additives

This paper describes a new method for the simultaneous determination of heavy metal ions in tobacco and tobacco additives by microcolumn high-performance liquid chromatography. The samples were digested by microwave digestion. The lead, cadmium, mercury, nickel, cobalt and tin ions in the digested samples were pre-column derivatized with tetra-(o-aminophenyl)- porphyrin (To-APP) to form coloured chelates. The Hg-To-APP, Cd-To-APP, Pb-To-APP, Ni-To-APP, Co-To-APP and Sn-To-APP chelates were enriched by solid phase extraction with a C18 cartridge resulting in an enrichment factor of 50. The chelates were separated on aWaters Xterra™ RP18 microcolumn (50mm×1.0 mm, 2.5 μm) with a mixture of methanol-tetrahydrofuran (95:5, v/v, containing 0.05 mol L–1 pyrrolidine-acetic acid buffer salt, pH=10.0) as mobile phase at a flow rate of 0.2 mL min–1 and identified with a photodiode array detector at 350–600 nm. The metal chelates were fully separated in 2.0 min. The detection limits for lead, cadmium, mercury, nickel, cobalt and tin in the original digested samples were 4 ng L–1, 3 ngL–1, 6 ngL–1, 5 ngL–1, 5 ngL–1 and 4 ng L–1, respectively. The relative standard deviation for five replicate samples was 2.65~3.24%. The standard recoveries were 95.6~108%. The method was applied with good results to the determination of lead, cadmium, mercury, nickel, cobalt and tin in tobacco and tobacco additives.KEYWORDS: Microcolumn high-performance liquid chromatography, tetra-(o-aminophenyl)-porphyrin, heavy metal ions

Initial Visible and Mid-IR Characterization of P/2019 LD₂ (ATLAS), an Active Transitioning Centaur Among the Trojans, with Hubble, Spitzer, ZTF, Keck, APO and GROWTH Imaging and Spectroscopy

We present visible and mid-infrared imagery and photometry of Jovian co-orbital comet P/2019 LD₂ (ATLAS) taken with Hubble Space Telescope/WFC3 on 2020 April 1, Spitzer Space Telescope/IRAC on 2020 January 25, Zwicky Transient Facility between 2019 April 9 and 2019 Nov 8 and the GROWTH telescope network from 2020 May to July, as well as visible spectroscopy from Keck/LRIS on 2020 August 19. Our observations indicate that LD₂ has a nucleus with radius 0.2-1.8 km assuming a 0.08 albedo and that the coma is dominated by ∼100 μ m-scale dust ejected at ∼1 m/s speeds with a ∼1" jet pointing in the SW direction. LD₂ experienced a total dust mass loss of ∼10⁸ kg and dust mass loss rate of ∼6 kg/s with Afρ/cross-section varying between ∼85 cm/125 km² and ∼200 cm/310 km² between 2019 April 9 and 2019 Nov 8. If the Afρ/cross-section increase remained constant, it implies that LD₂ has remained active since ∼2018 November when it came within 4.8 au of the Sun, a typical distance for comets to begin sublimation of H₂O. From our 4.5 μm Spitzer observations, we set a limit on CO/CO₂ gas production of ∼10²⁷/∼10²⁶ mol/s. Multiple bandpass photometry of LD₂ taken by the GROWTH network measured in a 10,000 km aperture provide color measurements of g-r = 0.59±0.03, r-i = 0.18±0.05, and i-z = 0.01±0.07, colors typical of comets. We set a spectroscopic upper limit to the production of H₂O gas of ∼80 kg/s. Improving the orbital solution for LD₂ with our observations, we determine that the long-term orbit of LD₂ is that of a typical Jupiter Family Comet having close encounters with Jupiter coming within ∼0.5 Hill radius in the last ∼3 y to within 0.8 Hill radius in ∼9 y and has a 95% chance of being ejected from the Solar System in < 10 Myr

Hypotensive effect and endothelium-dependent vascular action of leaves of Alpinia purpurata (Vieill) K. Schum

The aims of this study were to evaluate the chemical profile, vascular reactivity, and acute hypotensive effect (AHE) of the ethanolic extract of leaves of Alpinia purpurata (Vieill) K. Schum (EEAP). Its chemical profile was evaluated using HPLC-UV, ICP-OES, and colorimetric quantification of total flavonoids and polyphenols. The vascular reactivity of the extract was determined using the mesenteric bed isolated from WKY. AHE dose-response curves were obtained for both EEAP and inorganic material isolated from AP (IAP) in WKY and SHR animals. Cytotoxic and mutagenic safety levels were determined by the micronucleus test. Rutin-like flavonoids were quantified in the EEAP (1.8 ± 0.03%), and the total flavonoid and polyphenol ratios were 4.1 ± 1.8% and 5.1 ± 0.3%, respectively. We observed that the vasodilation action of EEAP was partially mediated by nitric oxide (·NO). The IAP showed the presence of calcium (137.76 ± 4.08 μg mg-1). The EEAP and IAP showed an AHE in WKY and SHR animals. EEAP did not have cytotoxic effects or cause chromosomic alterations. The AHE shown by EEAP could result from its endothelium-dependent vascular action. Rutin-like flavonoids, among other polyphenols, could contribute to these biological activities, and the calcium present in EEAP could act in a synergistic way

Study of e+e−→ppˉe^+e^- \rightarrow p\bar{p} in the vicinity of ψ(3770)\psi(3770)

Using 2917 $\rm{pb}^{-1}$ of data accumulated at 3.773~$\rm{GeV}$, 44.5~$\rm{pb}^{-1}$ of data accumulated at 3.65~$\rm{GeV}$ and data accumulated during a $\psi(3770)$ line-shape scan with the BESIII detector, the reaction $e^+e^-\rightarrow p\bar{p}$ is studied considering a possible interference between resonant and continuum amplitudes. The cross section of $e^+e^-\rightarrow\psi(3770)\rightarrow p\bar{p}$, $\sigma(e^+e^-\rightarrow\psi(3770)\rightarrow p\bar{p})$, is found to have two solutions, determined to be ($0.059\pm0.032\pm0.012$) pb with the phase angle $\phi = (255.8\pm37.9\pm4.8)^\circ$ ($<$0.11 pb at the 90% confidence level), or $\sigma(e^+e^-\rightarrow\psi(3770)\rightarrow p\bar{p}) = (2.57\pm0.12\pm0.12$) pb with $\phi = (266.9\pm6.1\pm0.9)^\circ$ both of which agree with a destructive interference. Using the obtained cross section of $\psi(3770)\rightarrow p\bar{p}$, the cross section of $p\bar{p}\rightarrow \psi(3770)$, which is useful information for the future PANDA experiment, is estimated to be either ($9.8\pm5.7$) nb ($<17.2$ nb at 90% C.L.) or $(425.6\pm42.9)$ nb

Global Retinoblastoma Presentation and Analysis by National Income Level

Importance: Early diagnosis of retinoblastoma, the most common intraocular cancer, can save both a child's life and vision. However, anecdotal evidence suggests that many children across the world are diagnosed late. To our knowledge, the clinical presentation of retinoblastoma has never been assessed on a global scale. Objectives: To report the retinoblastoma stage at diagnosis in patients across the world during a single year, to investigate associations between clinical variables and national income level, and to investigate risk factors for advanced disease at diagnosis. Design, Setting, and Participants: A total of 278 retinoblastoma treatment centers were recruited from June 2017 through December 2018 to participate in a cross-sectional analysis of treatment-naive patients with retinoblastoma who were diagnosed in 2017. Main Outcomes and Measures: Age at presentation, proportion of familial history of retinoblastoma, and tumor stage and metastasis. Results: The cohort included 4351 new patients from 153 countries; the median age at diagnosis was 30.5 (interquartile range, 18.3-45.9) months, and 1976 patients (45.4%) were female. Most patients (n = 3685 [84.7%]) were from low- A nd middle-income countries (LMICs). Globally, the most common indication for referral was leukocoria (n = 2638 [62.8%]), followed by strabismus (n = 429 [10.2%]) and proptosis (n = 309 [7.4%]). Patients from high-income countries (HICs) were diagnosed at a median age of 14.1 months, with 656 of 666 (98.5%) patients having intraocular retinoblastoma and 2 (0.3%) having metastasis. Patients from low-income countries were diagnosed at a median age of 30.5 months, with 256 of 521 (49.1%) having extraocular retinoblastoma and 94 of 498 (18.9%) having metastasis. Lower national income level was associated with older presentation age, higher proportion of locally advanced disease and distant metastasis, and smaller proportion of familial history of retinoblastoma. Advanced disease at diagnosis was more common in LMICs even after adjusting for age (odds ratio for low-income countries vs upper-middle-income countries and HICs, 17.92 [95% CI, 12.94-24.80], and for lower-middle-income countries vs upper-middle-income countries and HICs, 5.74 [95% CI, 4.30-7.68]). Conclusions and Relevance: This study is estimated to have included more than half of all new retinoblastoma cases worldwide in 2017. Children from LMICs, where the main global retinoblastoma burden lies, presented at an older age with more advanced disease and demonstrated a smaller proportion of familial history of retinoblastoma, likely because many do not reach a childbearing age. Given that retinoblastoma is curable, these data are concerning and mandate intervention at national and international levels. Further studies are needed to investigate factors, other than age at presentation, that may be associated with advanced disease in LMICs

Global Retinoblastoma Presentation and Analysis by National Income Level.

Importance: Early diagnosis of retinoblastoma, the most common intraocular cancer, can save both a child's life and vision. However, anecdotal evidence suggests that many children across the world are diagnosed late. To our knowledge, the clinical presentation of retinoblastoma has never been assessed on a global scale. Objectives: To report the retinoblastoma stage at diagnosis in patients across the world during a single year, to investigate associations between clinical variables and national income level, and to investigate risk factors for advanced disease at diagnosis. Design, Setting, and Participants: A total of 278 retinoblastoma treatment centers were recruited from June 2017 through December 2018 to participate in a cross-sectional analysis of treatment-naive patients with retinoblastoma who were diagnosed in 2017. Main Outcomes and Measures: Age at presentation, proportion of familial history of retinoblastoma, and tumor stage and metastasis. Results: The cohort included 4351 new patients from 153 countries; the median age at diagnosis was 30.5 (interquartile range, 18.3-45.9) months, and 1976 patients (45.4%) were female. Most patients (n = 3685 [84.7%]) were from low- and middle-income countries (LMICs). Globally, the most common indication for referral was leukocoria (n = 2638 [62.8%]), followed by strabismus (n = 429 [10.2%]) and proptosis (n = 309 [7.4%]). Patients from high-income countries (HICs) were diagnosed at a median age of 14.1 months, with 656 of 666 (98.5%) patients having intraocular retinoblastoma and 2 (0.3%) having metastasis. Patients from low-income countries were diagnosed at a median age of 30.5 months, with 256 of 521 (49.1%) having extraocular retinoblastoma and 94 of 498 (18.9%) having metastasis. Lower national income level was associated with older presentation age, higher proportion of locally advanced disease and distant metastasis, and smaller proportion of familial history of retinoblastoma. Advanced disease at diagnosis was more common in LMICs even after adjusting for age (odds ratio for low-income countries vs upper-middle-income countries and HICs, 17.92 [95% CI, 12.94-24.80], and for lower-middle-income countries vs upper-middle-income countries and HICs, 5.74 [95% CI, 4.30-7.68]). Conclusions and Relevance: This study is estimated to have included more than half of all new retinoblastoma cases worldwide in 2017. Children from LMICs, where the main global retinoblastoma burden lies, presented at an older age with more advanced disease and demonstrated a smaller proportion of familial history of retinoblastoma, likely because many do not reach a childbearing age. Given that retinoblastoma is curable, these data are concerning and mandate intervention at national and international levels. Further studies are needed to investigate factors, other than age at presentation, that may be associated with advanced disease in LMICs